109 related articles for article (PubMed ID: 30904164)
1. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma.
Nakagawa N; Kikuchi K; Yagyu S; Miyachi M; Iehara T; Tajiri T; Sakai T; Hosoi H
Biochem Biophys Res Commun; 2019 May; 512(3):524-530. PubMed ID: 30904164
[TBL] [Abstract][Full Text] [Related]
2. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
Wada M; Horinaka M; Yamazaki T; Katoh N; Sakai T
PLoS One; 2014; 9(11):e113217. PubMed ID: 25422890
[TBL] [Abstract][Full Text] [Related]
3.
Dolgikh N; Hugle M; Vogler M; Fulda S
Cancer Res; 2018 Apr; 78(8):2000-2013. PubMed ID: 29437705
[TBL] [Abstract][Full Text] [Related]
4. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
[TBL] [Abstract][Full Text] [Related]
5. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
6. MEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy.
Tanaka T; Higashi M; Kimura K; Wakao J; Fumino S; Iehara T; Hosoi H; Sakai T; Tajiri T
J Pediatr Surg; 2016 Dec; 51(12):2074-2079. PubMed ID: 27686482
[TBL] [Abstract][Full Text] [Related]
7. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
[TBL] [Abstract][Full Text] [Related]
8. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma.
Martinelli S; McDowell HP; Vigne SD; Kokai G; Uccini S; Tartaglia M; Dominici C
Genes Chromosomes Cancer; 2009 Nov; 48(11):975-82. PubMed ID: 19681119
[TBL] [Abstract][Full Text] [Related]
9. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by RAS/RAF mutations.
Agaram NP; Huang SC; Tap WD; Wexler LH; Antonescu CR
Genes Chromosomes Cancer; 2022 Mar; 61(3):131-137. PubMed ID: 34755412
[TBL] [Abstract][Full Text] [Related]
11. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y
Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851
[TBL] [Abstract][Full Text] [Related]
12. Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma.
Hensch NR; Bondra K; Wang L; Sreenivas P; Zhao XR; Modi P; Vaseva AV; Houghton PJ; Ignatius MS
Mol Cancer Ther; 2023 Jan; 22(1):123-134. PubMed ID: 36162055
[TBL] [Abstract][Full Text] [Related]
13. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
[TBL] [Abstract][Full Text] [Related]
14. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.
Stewart E; McEvoy J; Wang H; Chen X; Honnell V; Ocarz M; Gordon B; Dapper J; Blankenship K; Yang Y; Li Y; Shaw TI; Cho JH; Wang X; Xu B; Gupta P; Fan Y; Liu Y; Rusch M; Griffiths L; Jeon J; Freeman BB; Clay MR; Pappo A; Easton J; Shurtleff S; Shelat A; Zhou X; Boggs K; Mulder H; Yergeau D; Bahrami A; Mardis ER; Wilson RK; Zhang J; Peng J; Downing JR; Dyer MA;
Cancer Cell; 2018 Sep; 34(3):411-426.e19. PubMed ID: 30146332
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog signal inhibitor forskolin suppresses cell proliferation and tumor growth of human rhabdomyosarcoma xenograft.
Yamanaka H; Oue T; Uehara S; Fukuzawa M
J Pediatr Surg; 2011 Feb; 46(2):320-5. PubMed ID: 21292081
[TBL] [Abstract][Full Text] [Related]
17. Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma.
Li S; Fu J; Yang J; Ma H; Bhutani D; Mapara MY; Marcireau C; Lentzsch S
Blood; 2021 Apr; 137(13):1754-1764. PubMed ID: 33036022
[TBL] [Abstract][Full Text] [Related]
18. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.
Schaaf G; Hamdi M; Zwijnenburg D; Lakeman A; Geerts D; Versteeg R; Kool M
Cancer Res; 2010 Jan; 70(2):762-71. PubMed ID: 20068162
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.
Okumura S; Jänne PA
Clin Cancer Res; 2014 Aug; 20(16):4193-9. PubMed ID: 24907112
[TBL] [Abstract][Full Text] [Related]
20. Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.
Teot LA; Schneider M; Thorner AR; Tian J; Chi YY; Ducar M; Lin L; Wlodarski M; Grier HE; Fletcher CDM; van Hummelen P; Skapek SX; Hawkins DS; Wagers AJ; Rodriguez-Galindo C; Hettmer S
Cancer; 2018 May; 124(9):1973-1981. PubMed ID: 29461635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
